Inhibrx CEO Mark Lappe Purchases $2.6 Million Worth of Shares
On September 8, 2026, Inhibrx Biosciences' founder and CEO, Mark Lappe, acquired 25,000 shares for a total value of $2.6 million through multiple transactions at prices ranging from $98.88 to $112.44 per share. The purchase increased his indirect beneficial ownership in the company to approximately 950,000 shares or about 6% of Inhibrx's outstanding equity. The CEO’s investment was made via a weighted average cost basis of $105.82 and is held through various trusts and retirement accounts, including family entities. This move comes as the company continues to operate in a development-stage business model with no revenue yet but significant investor interest due to its proprietary modular protein engineering platforms for biologic therapeutics. Inhibrx reported a trailing twelve-month net loss of $138.2 million and has a market capitalization of approximately $1.4 billion as of the transaction date, reflecting typical dynamics in clinical-stage biotechnology firms.
Tickers: $INBX
Topics: biotechnology CEO activity stock purchase